Company: ATRA
Filing Date: 2025-05-16
Form Type: SCHEDULE 13D/A
Source: 0001104659-25-050119
Chunk: 0

Company: Atara Biotherapeutics, Inc.
Filing Date: 2025-05-16
Form: SCHEDULE 13D/A
Chunk 0
---
0.00   
                                                                     10  1,370,081.00 |
| 11                                                                 |                                                                         1,370,081.00 |
| 12                                                                 | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions) |
| 13                                                                 |                                                                              19.99 % |
| 14                                                                 |                                                                                   IA |

Comment for Type of Reporting Person: (1) Adiumentum Capital Fund I LP's beneficial ownership of the reported securities is comprised of 1,209,395 shares of Common Stock (as defined below) and 160,686 shares of Common Stock issuable upon exercise of Pre-Funded Warrants (as defined below) which may be exercised as of the date hereof without exceeding the Beneficial Ownership Limitation (as defined below). The reported securities may also be deemed beneficially owned by Adiumentum Capital Fund I GP LLC and Gregory A. Ciongoli, each of which or whom disclaim beneficial ownership of these shares, except to the extent of its or his pecuniary interest in such shares, if any. Adiumentum Capital Fund I LP also holds Pre-Funded Warrants for 216,507 shares of Common Stock that are not currently exercisable due to the Beneficial Ownership Blocker (as defined below). Pursuant to the terms of the Pre-Funded Warrants, the Issuer may not effect any exercise of any Pre-Funded Warrant, and a holder of a Pre-Funded Warrant does not have the right to exercise any portion of the Pre-Funded Warrant held by such holder, to the extent that, after giving effect to the attempted exercise set forth in a notice of exercise, such holder, together with such holder's affiliates and any other person whose beneficial ownership of Common Stock would be aggregated with such holder's for the purposes of Section 13(d) of the Act, and the applicable regulations of the U.S. Securities and Exchange Commission (the "SEC"), including any "group" of which such holder is a member, would beneficially own a number of shares of Common Stock in excess of the Beneficial Ownership Limitation (the "Beneficial Ownership Blocker"). The "Beneficial Ownership Limitation" is 19.99% of the shares of Common Stock then issued and outstanding, which percentage may be changed at a holder's election upon 61 days' notice to the Issuer. The 1,209,395 shares of Common Stock and 160,686 shares